PL449237A1 - Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel - Google Patents

Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel

Info

Publication number
PL449237A1
PL449237A1 PL449237A PL44923724A PL449237A1 PL 449237 A1 PL449237 A1 PL 449237A1 PL 449237 A PL449237 A PL 449237A PL 44923724 A PL44923724 A PL 44923724A PL 449237 A1 PL449237 A1 PL 449237A1
Authority
PL
Poland
Prior art keywords
paclitaxel
treatment
inhibitor
small cell
cell lung
Prior art date
Application number
PL449237A
Other languages
English (en)
Inventor
Agnieszka Robaszkiewicz
Original Assignee
Uniwersytet Łódzki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Łódzki filed Critical Uniwersytet Łódzki
Priority to PL449237A priority Critical patent/PL449237A1/pl
Publication of PL449237A1 publication Critical patent/PL449237A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest inhibitor do zastosowania w leczeniu nowotworów opornych na paklitaksel, przy czym inhibitor SGC-CBP30 jest inhibitorem enzymu acetylotransferazy EP300/CBP. Inhibitor przeznaczony jest zwłaszcza do zastosowania w leczeniu opornych na paklitaksel niedrobnokomórkowego raka płuc i/lub potrójnie negatywnego nowotworu piersi u pacjentów poddanych wcześniejszej chemioterapii paklitakselem, u których nowotwory te wykształciły oporność na paklitaksel.
PL449237A 2024-07-15 2024-07-15 Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel PL449237A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL449237A PL449237A1 (pl) 2024-07-15 2024-07-15 Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL449237A PL449237A1 (pl) 2024-07-15 2024-07-15 Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel

Publications (1)

Publication Number Publication Date
PL449237A1 true PL449237A1 (pl) 2026-01-19

Family

ID=98430731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL449237A PL449237A1 (pl) 2024-07-15 2024-07-15 Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel

Country Status (1)

Country Link
PL (1) PL449237A1 (pl)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044694A1 (en) * 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2020101571A1 (en) * 2018-11-12 2020-05-22 Agency For Science, Technology And Research Methods for manipulating cell state transitions in cancer
WO2021260109A1 (en) * 2020-06-25 2021-12-30 Tolremo Therapeutics Ag A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC
PL440432A1 (pl) * 2022-02-22 2023-08-28 Uniwersytet Łódzki Inhibitor acetylotransferazy do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044694A1 (en) * 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2020101571A1 (en) * 2018-11-12 2020-05-22 Agency For Science, Technology And Research Methods for manipulating cell state transitions in cancer
WO2021260109A1 (en) * 2020-06-25 2021-12-30 Tolremo Therapeutics Ag A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC
PL440432A1 (pl) * 2022-02-22 2023-08-28 Uniwersytet Łódzki Inhibitor acetylotransferazy do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi

Similar Documents

Publication Publication Date Title
O'Sullivan et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
Truong et al. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy
Elias et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy
Levine et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures
Jackson et al. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
Sohn et al. Primary tumor location impacts breast cancer survival
Holloway et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients
Mazouni et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures
Bayon et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Geng et al. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells
Andreetta et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
Trovik et al. Consequences of local recurrence of soft tissue sarcoma: 205 patients from the Scandinavian Sarcoma Group Register
Qian et al. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer
Dawood et al. The medical treatment of inflammatory breast cancer
Ogita et al. Clinical outcome of adjuvant radiotherapy for squamous cell carcinoma of the breast; a multicenter retrospective cohort study
Viani et al. Patients with N1 breast cancer: who could benefit from supraclavicular fossa radiotherapy?
Chen et al. Angiosarcoma of the lung: 2 cases report and literature reviewed
PL449237A1 (pl) Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel
Kurokawa et al. Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)
Matuschek et al. Neoadjuvant Radio (chemo) therapy for breast cancer: an old concept revisited
Suidan et al. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer
Yang et al. The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery
Hotokezaka et al. Factors influencing outcome after surgery for stage IV colorectal cancer
Sugiura et al. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma
Nomori et al. Primary malignant lymphoma of superior vena cava